Trio Labs raises $3.8M, seeks to enable next gen medical devices
Summary
RESEARCH TRIANGLE PARK – Trio Labs has raised $3,820,669 in equity from 36 investors, according to an SEC filing. The company, based in Research Triangle Park, fabricates precision metal parts through its proprietary processes that allow manufacturers to scale quickly and effectively from rapid prototyping to full production, and uses a patent-pending technology, Resin Infused Powder Lithography (RIPL). “Additive Manufacturing has long been a favorite of design engineers for its ability to produce complex geometries,” reads the company’s website. “RIPL brings this design flexibility to a production level, allowing for previously impossible devices to be made in high volume.” According to the company, its technology is compatible with any alloy or other ceramic that’s used in powder injection molding. The proceeds of the sale will be used for working capital, according to the filing, which the company notes may include compensation to executive officers.